CN101491648A - Composite lipid adjustment medicine - Google Patents
Composite lipid adjustment medicine Download PDFInfo
- Publication number
- CN101491648A CN101491648A CNA2008100043035A CN200810004303A CN101491648A CN 101491648 A CN101491648 A CN 101491648A CN A2008100043035 A CNA2008100043035 A CN A2008100043035A CN 200810004303 A CN200810004303 A CN 200810004303A CN 101491648 A CN101491648 A CN 101491648A
- Authority
- CN
- China
- Prior art keywords
- medicine
- extract
- sacchari sinensis
- caulis sacchari
- monas cuspurpureus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a compound lipid-regulating medicine, and in particular provides a compound medicine with pure naturally sourced active components for treating hyperlipidemia or atherosclerosis. The compound medicine is characterized by taking monascus and sugar-cane extract as main medicines. The compound lipid-regulating medicine has the advantages of reducing monascus dosage and then toxic-side effects and improving efficacy.
Description
Technical field
The present invention relates to a kind of composite lipid-regulation medicine, a kind of compound medicine for the treatment of the pure natural source active ingredient of hyperlipemia or atherosclerosis especially is provided.Belong to field of medicaments.
Background technology
Monas cuspurpureus Went is commonly called as " red bent ", it is traditional simply medical material, for being inoculated in the rice top fermentation, the monascus fungus Mauve aspergillar Monascus purpureus Went of Monas cuspurpureus Went section forms, contain materials such as Monas cuspurpureus Went saccharifying enzyme, amylase, monascorubin, several amino acids, organic acid in the tunning, very favourable to human body, serve many purposes, " clear different record " beginning that later stage Tang Dynasty Tao Gu writes is on the books, all the time, it uses mainly as fermented food and food coloring.Ming Dynasty's Li Shizhen (1518-1593 A.D.) is promptly studied the Monas cuspurpureus Went medical value, development of modern science and technology, and the medical value of Monas cuspurpureus Went more and more receives publicity.Contain Mo Na Kelin (monacolins) series material in the Monas cuspurpureus Went, have effects such as blood fat reducing, blood sugar lowering, resisting fatigue, enhancing immunity, bacteria growing inhibiting breeding, the world all is devoted in the Duo Jia pharmaceutical factory developmental research of Monas cuspurpureus Went, and entering clinical operational phase, first medicine in " Statins " fat regulation medicine---lovastatin promptly is that Japanese scholar 1979 obtains by separating in the Monas cuspurpureus Went.
Caulis Sacchari sinensis is the crop of tool nutrition and health care function, its function provides heat energy and the sweet taste the people except Caulis Sacchari sinensis, in China's tradition in the medical book early relevant for the record of Caulis Sacchari sinensis health care, all mention in " Mingyi Bielu " as " gods and spirits' opinion " of oneth century of Christian era Dongfang Shuo, Northern and Southern Dynasties' TAO Hong-Jing: sugarcane juice can lung moistening gas, help the five internal organs gas, promote the production of body fluid relieve the effect of alcohol detoxifcation, neutralize, help temper, delay irritability etc.; Contain various active compositions such as many arachyl alcohols, Polyphenols polyphenoils, oligomeric xylose, plant sterol in the Caulis Sacchari sinensis extract.
Though compare with simple Lovastatin, containing under the identical Lovastatin dosage situation Monas cuspurpureus Went has reduced and has taken the Statins lipid-regulation medicine for a long time and issuable toxic and side effects, tire and tally with the national condition, but, clinical in recent years use shows, Monas cuspurpureus Went can cause all untoward reaction due to the Statins, simultaneously, owing to contain Citrinin in the Monas cuspurpureus Went, its target organ is a kidney, is also referred to as the nephrotoxin, can suppress the α-Tong Wuersuan in renal cortex and the hepatic mitochondria and the activity of pyruvic dehydrogenase, thereby reduce the absorption of mitochondrion to calcium ion, influence film and shift and oxidation-reduction system, cause the infringement of kidney 26S Proteasome Structure and Function, sexual dysfunctions etc. also have teratogenecity, in the toxicity and the further at present further investigation of mechanism to other organs and cell, but exist potential danger.
Summary of the invention
The purpose of this invention is to provide a kind of composite lipid-regulation medicine,, reduce toxicity, improve therapeutic effect to reduce dosage.
For achieving the above object, technical solution of the present invention is as follows:
The invention provides a kind of composite lipid-regulation medicine, it is characterized in that with Monas cuspurpureus Went and Caulis Sacchari sinensis extract be principal agent.
Above-mentioned described composite lipid-regulation medicine wherein, calculates Monas cuspurpureus Went 1-60 part, Caulis Sacchari sinensis extract 1-5 part by weight.
Wherein, as preferably, calculate by weight, in the described medicine, Monas cuspurpureus Went is 2-60 part, Caulis Sacchari sinensis extract 2-3 part.
The above-mentioned described medicine of the present invention wherein, if necessary, can also comprise acceptable accessories, for example, according to the needs of dosage form, can select conventional adjuvants such as suitable medicinal excipient, filler, lubricant for use.
As the present invention's one specific embodiments, described composite lipid-regulation medicine is a compound preparation, and the per unit compound preparation contains Monas cuspurpureus Went 10～300mg, Caulis Sacchari sinensis extract 1～300mg; Especially, the per unit compound preparation contains principal agent 300mg, Monas cuspurpureus Went 10～300mg wherein, Caulis Sacchari sinensis extract 1～300mg.
The above-mentioned described composite lipid-regulation medicine of the present invention, wherein said Caulis Sacchari sinensis extract, containing compositions such as many arachyl alcohols, Polyphenols polyphenoils, plant sterol, oligomeric xylose, is the Caulis Sacchari sinensis extract that is prepared by extraction, separation, the purification process of sugarcane raw material by this area routine.Wherein, preferred described Caulis Sacchari sinensis extract contains and is not less than many arachyl alcohols of 90%.
Especially, the above-mentioned described composite lipid-regulation medicine of the present invention, wherein said Caulis Sacchari sinensis extract are to make by the method that comprises one of following or a plurality of steps:
(1) extracts many arachyl alcohols;
(2) extract the Polyphenols polyphenoils;
(3) extract plant sterol;
(4) extract oligomeric xylose.
Wherein, the many arachyl alcohols of described extraction can be by conventional from advanced wax or oils and fats (comprising cerosin) many arachyl alcohols of extraction separation technology, for example solvent extraction method and supercritical fluid extraction in this area.
1) solvent extraction method for example can be selected organic solvents commonly used such as acetone, positive butanone, methanol, ethanol, hexane, heptane, chloroform and benzene for use.
2) supercritical extraction method can obtain many arachyl alcohols product (wherein containing octacosanol about 50%), and no solvent residue is in product, and yield is than solvent method height.
In addition, also can select for use methods such as chemical ester exchange process, reducing process and molecular distillation technique to extract high-carbon fatty alcohols such as many arachyl alcohols.
For the analytical method of many arachyl alcohols, can adopt the capillary column gas chromatography method, on the HP-5 post, between octacosanol, triacontanol and other kind high-carbon fatty alcohols and the internal standard substance TPB separating effect is preferably arranged.
Wherein, the extracting method of described Polyphenols polyphenoils can extract polyphenols from peace and quiet sugarcane tip juice by conventional extraction separation method.For example with the following method optional:
1) solvent extraction;
2) ion precipitation method;
3) adsorption column partition method;
4) supercritical carbon dioxide extraction method.
Wherein, the extraction of described plant sterol, the method for extraction plant sterol that can be by this area routine is extracted from Caulis Sacchari sinensis and is obtained.As an example, can obtain plant sterol by the following method.
1) extracts plant sterol from Caulis Sacchari sinensis filter mud sugarcane fat
The Caulis Sacchari sinensis dry filter mud goes out waxy stone with solvent extraction, when with acetone or other suitable solvent refined cane wax, acetone insoluble matter is a cerosin, and another part is a sugarcane fat for the acetone soluble matters, solid-liquid separation gets the extractive lipoid solution of acetone, steams that (recovery reuse) just is sugarcane fat behind the acetone.Have 20%～30% to be sugarcane fat in the waxy stone approximately, sugarcane fat is oils or paste, contain chemical compounds such as glycerolipid, steroid, fatty acid, behind the sugarcane fat alkaline saponification, collect not saponification part, obtain plant sterol, the plant sterol about 20% in the sugarcane fat is stigmasterol (Stigmasterol), and about 80% is α-sitoesterol (α-Sitosterol).
2) from Cortex Sacchari sinensis, extract cupreol
Get Cortex Sacchari sinensis and clean, in water, soak 2～3 days to remove sucrose.Be cut into the fritter of 3～4mm after the drying, take by weighing 200g, respectively with twice of ethanol 700ml, 500ml reflux, extract,, each backflow 8h, with the ethanol extract thin film concentration to syrupy shape, add 10% hydrochloric acid 100ml and in boiling water bath hydrolysis 1.5h, hydrolysate is used ethyl acetate 5Oml respectively, 25ml extracts three times, the pressure reducing and steaming ethyl acetate.Residue carries out low pressure column chromatography with the 40g silica gel H.Wash away the little impurity of polarity with bp60～90 ℃ petroleum ether, with petroleum ether-ethyl acetate (10: 1) eluting and with thin layer chromatography monitoring eluent, boil off eluent again, the cupreol of collecting is made with extra care with ethanol.
3) from bagasse, extract cupreol
Bagasse is cleaned, and water dumping is soaked three days (changing water three times) and is removed the sucrose after drying, cuts into the fragment about 1cm.Take by weighing bagasse 200g, extract 8h with 95% ethanol 800ml reflux, incline ethanol extract after, add 95% ethanol 700ml reflux again and extract 8h, incline and ethanol extract and merge with above-mentioned ethanol extract, pressure reducing and steaming ethanol. residue is with 10% hydrochloric acid 100ml hydrolysis 2h in boiling water, use ethyl acetate 50ml after the cooling respectively, 25ml, 25ml extracts hydrolyzed solution three times, the combined ethyl acetate extracting solution, using anhydrous sodium sulfate drying, concentrating under reduced pressure to boil off ethyl acetate after washing with water gets the syrupy shape residue, residue is carried out low pressure column chromatography with the 40g silica gel H, with petroleum ether-ethyl acetate (9: 1) eluting, get cupreol.
Wherein, the extraction of described oligomeric xylose, the way that can adopt poly-polysaccharide to degrade.For example can adopt enzyme hydrolysis method.
As an example, can adopt enzymatic isolation method to prepare oligomeric xylose by following link by bagasse: raw material (bagasse), water → xylan extract → make with extra care → refining xylan liquid → enzymatic degradation → thick product → refining concentrating → mill run → further purification → high purity product.Specifically:
1) bagasse pretreatment.
The preprocess method of bagasse has:
(1) physics method: comprise ball milling, compression ball milling, explosion pulverizing, freezing and pulverizing, gamma-radiation, sound wave, electron ray etc. all can make cellulose efflorescence, softening, the cellulosic enzymolysis conversion ratio of raising.
(2) chemical method: process for chemically pretreating has methods such as mineral acid, alkali and organic solvent.Its mechanism mainly is that solvent makes cellulose, hemicellulose and lignin imbibition and destroys its crystallinity, makes bagasse dissolving, degraded, thereby increases digestibility.
(3) physical-chemical method: the strong point of main synthesis logos and chemical method compensates its defect.For example combination of combination, chemical addition agent and the supercritical reaction of chemical addition agent and steam explosion method or the like.
(4) bioanalysis: what be usually used in lignin degrading is white rot fungus, brown rot fungus, soft rot fungus and some antibacterial.
2) extraction of xylan.With bagasse is that raw material can extract xylan by the extracting method of routine, for example can extract xylan, xylan extracted with alkali or acid system and extract xylan by high-temperature cooking process, the perhaps combination of distinct methods, for example the method for wet method steaming and decocting after carrying out sour pretreatment on the basis of high-temperature cooking process improves extraction efficiency.
3) hydrolysis of xylan prepares oligomeric xylose.Can select conventional method for hydrolysis for use, preferably adopt enzymatic isolation method, what for example utilize that endo-xylanase hydrolyzed xylan substrate obtains is the mixture of main component with 1,4-.beta.-Xylobiose, xylotriose.
4) purification of oligomeric xylose.Can obtain high-purity oligomeric xylose by the purification process of routine, for example adopt ion exchange resin and membrane filtration to carry out separation and purification,, can obtain high-purity oligomeric xylose product with the processing of decolouring of activated carbon, kieselguhr.
In the composite lipid-regulation medicine of the present invention, principal agent is Monas cuspurpureus Went and Caulis Sacchari sinensis extract, wherein Monas cuspurpureus Went has the effect of potent accent fat, and the octacosanol that contains in the Caulis Sacchari sinensis extract has stronger effect for reducing blood fat, and Polyphenols and plant sterol also have certain effect for reducing blood fat, in addition, regulate cardiovascular function, integrate metabolic process, effects such as control atherosclerosis, the composite lipid-regulation medicine of the present invention that the two use in conjunction is formed, drug action is auxilliary mutually old mutually, complement one another, the performance synergistic function is significantly higher than the drug effect that Monas cuspurpureus Went or Caulis Sacchari sinensis extract have respectively.
And in the composite lipid-regulation medicine of the present invention, the time-concentration relationship of Monas cuspurpureus Went and the time-concentration relationship of Caulis Sacchari sinensis extract can cooperatively interact, thereby also can not cause the mutual interference of administration phase so that the problem of making troubles.
Especially, in the composite lipid-regulation medicine of the present invention, the dosage of Monas cuspurpureus Went is greatly turned down with respect to the dosage of single Monas cuspurpureus Went, and the medicine fat regulation medicine imitates activity and not only do not weaken, and is stronger with respect to single Monas cuspurpureus Went.Therefore Monas cuspurpureus Went alleviates the serious adverse reaction of rhabdomyolysis in the composite lipid-regulation medicine of the present invention, and incidence rate reduces, and accomplishes more safe and effective.
In a word, a kind of novel accent fat that composite lipid-regulation medicine of the present invention, the two drug combination of Monas cuspurpureus Went and Caulis Sacchari sinensis extract form, the medicine of preventing arteriosclerosis, not only increased drug effect, and reduced the Monas cuspurpureus Went dosage, and then reduced the untoward reaction effect of Monas cuspurpureus Went, medicine is safer.
The specific embodiment
Further specify content of the present invention by the following examples, but do not constitute restriction rights protection scope of the present invention.
Embodiment one: the Caulis Sacchari sinensis extract preparation
It is an amount of to get sugarcane wax, fusing in advance, in homogeneous phase, use 10 to 20% concentrated sodium hydroxides that account for wax weight, calcium hydroxide or potassium hydroxide solution saponification 3 to 10 hours, use the organic solvent normal hexane then, acetone, methyl, ethyl ketone, methanol, ethanol or isopropyl alcohol, chloroform, dichloromethane, 1, the 2-dichloroethanes, benzene, toluene or their mixture optionally extract alcohol mixture in the solid-liquid extraction system, extracted altogether 15 to 20 hours, recrystallization goes out in above-mentioned solvent or their mixture then, obtain Caulis Sacchari sinensis extract, be a kind of off-white color or the crystallization of yellow powder powder, be arachyl alcohol more than 24 to 34 carbon atoms, account for total extract weight more than 90%, wherein octacosanol content is the highest, is 60%～70%; Tetracosanol is about 2%, and hexacosanol is about 4.52%～10%, and heptacosanol is about 5%, and nonacosanol is about 2%, triacontanol 10%～15%, and n-Dotriacontanol is about 3%～8%, inearnatyl alcohol about 2%.
Example two: the red capsule of sugarcane
1, specification: 300mg
2, prescription:
Monas cuspurpureus Went 290.0g
Caulis Sacchari sinensis extract (wherein contain be not less than 90% many arachyl alcohols) 10.0g
Lactose 60.0g
Sodium bicarbonate 12.0g
Cross-linking sodium carboxymethyl cellulose 1.5g
2% hypromellose, 30% alcoholic solution is an amount of
Silica 1 .5g
Magnesium stearate 0.4g
Make 1000
3, preparation process
(1) preparation of binding agent: take by weighing hypromellose and in purified water, dissolve, add an amount of ethanol, be diluted to 2% hypromellose, 30% alcoholic solution, standby;
(2) adjuvant is handled: after lactose, cross-linking sodium carboxymethyl cellulose, sodium bicarbonate were crossed 100 mesh sieves respectively, it was standby to take by weighing recipe quantity;
(3) mixing: after Monas cuspurpureus Went, many arachyl alcohols are crossed 120 mesh sieves, take by weighing recipe quantity, with above-mentioned in add adjuvant with the equivalent method mixing that progressively increases;
(4) system soft material: with 2% hypromellose, 30% alcoholic solution system soft material;
(5) granulate: 20 mesh sieves are granulated;
(6) oven dry: dry under 60 ℃ of conditions;
(7) granulate: 18 mesh sieve granulate;
(8) add silicon dioxide, magnesium stearate mixing;
(9) product detect in the middle of;
(10) capsule fill;
(11) full inspection;
(12) packing, preservation.
Example three: the red tablet of sugarcane
1, specification: 300mg
2, label prescription:
Monas cuspurpureus Went 290.0g
Caulis Sacchari sinensis extract (wherein contain be not less than 90% many arachyl alcohols) 10.0g
Lactose 73.6g
Cross-linking sodium carboxymethyl cellulose 3.2g
Sodium bicarbonate 8.5g
Silica 1 .6g
Pulvis Talci 1.6g
Magnesium stearate 0.5g
2% hypromellose is an amount of
50% alcoholic solution is an amount of
Make 1000
3, preparation process
(1) preparation of binding agent: take by weighing hypromellose and in purified water, dissolve, add an amount of ethanol, be diluted to 2% hypromellose, 50% alcoholic solution, standby;
(2) adjuvant is handled: after lactose, 1/2 cross-linking sodium carboxymethyl cellulose, sodium bicarbonate were crossed 100 mesh sieves respectively, it was standby to take by weighing recipe quantity;
(3) mixing: Monas cuspurpureus Went, many arachyl alcohols take by weighing recipe quantity after crossing 200 sieves, with above-mentioned in add adjuvant with the equivalent method mixing that progressively increases;
(4) system soft material: with 2% hypromellose, 50% alcoholic solution system soft material;
(5) granulate: 20 mesh sieves are granulated
(6) 60 ℃ of forced air dryings;
(7) granulate: 18 mesh sieve granulate;
(8) add recipe quantity magnesium stearate and 1/2 cross-linked carboxymethyl cellulose, mix homogeneously;
(9) product detect in the middle of;
(10) select ф 6mm shallow concave punch for use, regulate pressure, tabletting;
(11) full inspection;
(12) packing, preservation.
Embodiment four: the pharmacodynamic studies of the red compound preparation of sugarcane
Choose rat, preparation hyperlipidemia model, the effect of the red compound preparation blood lipid regulation of research sugarcane.Experimental rat is divided into 7 groups, when giving high lipid food, matched group gives distilled water, experimental group gives the red compound preparation of sugarcane of high, medium and low dosage (1000,500,100mg/kg), continuous 28d, rat blood serum triglyceride (TG), low density lipoprotein, LDL (LDL-C), serum cholesterol (TC) level level are starkly lower than high fat matched group, serum high-density LP cholesterol (HDL-C) level is apparently higher than high fat matched group, and the red compound recipe fixture of visible sugarcane of the present invention has the accent blood fat that is better than Monas cuspurpureus Went and lovastatin.
1, laboratory animal grouping
70 of SD male rats, body weight 200～230g, level according to serum cholesterol and triglyceride is divided into 7 groups at random, (dosage with Monas cuspurpureus Went is contrast for normal control group, high lipid food matched group, Monas cuspurpureus Went group (1000mg/kg), lovastatin group (15mg/kg), the high, medium and low dosage group of the red compound preparation of sugarcane, be respectively 250,500,1000mg/kg) 3 dosage groups, 10 every group.
2, method
2.1 normal feedstuff prescription (%) flour 53, rice flour 1918, Semen Maydis powder 718, Testa Tritici 310, yeast 415, casein 110, whole milk powder 415, analysis for soybean powder 310, bone meal 112, cod-liver oil 112, salt 110.
2.2 high lipid food prescription (%) normal feedstuff 79, cholesterol 1, yolk powder 10, Adeps Sus domestica 10.
2.3 the experimental drug Monas cuspurpureus Went is available from Zhuozhou, Hebei Bioisystech Co., Ltd, Caulis Sacchari sinensis extract obtains according to embodiment 1 preparation method, and Main Ingredients and Appearance is 1-octacosanol, 1-n-Dotriacontanol, 1-triacontanol, 1-tetracosanol, 1-inearnatyl alcohol, 1-hexacosanol, 1-heptacosanol and 1-nonacosanol.According to Monas cuspurpureus Went: Caulis Sacchari sinensis extract is that 29: 1 systems are made into the red compound preparation of sugarcane.
(temperature is 20 ℃～23 ℃ 2.4 experimental program is in experimental situation, relative humidity is 40%～60% shielding harness) following rat nursing normal feedstuff 5d, get tail vein on an empty stomach after the fasting, measure TG in the serum, TC, according to TC, consider TG level and body weight situation, random packet, when giving high lipid food, test group gives the Monas cuspurpureus Went of corresponding dosage respectively, lovastatin, the red compound recipe system of sugarcane, blank group and high fat matched group give distilled water, irritate stomach every day, continuous 28d, weigh in weekly, get tail vein respectively at the 14th day and 28d, measure the total TG of serum with Lisa-500Plus type automatic clinical chemistry analyzer, total TC, LDL-C, the HDL-C level.Triglyceride with phosphoglycerol oxidizing process, cholesterol with enzyme assay, the HDL-C sedimentation method.
2.5 date processing carries out the variance analysis statistics with SPSS12.
3, result
The content of TC, TG, LDL-C all is significantly higher than the blank group in the model group rat blood serum, and the horizontal highly significant of Serum HDL-C is lower than blank group (P＜0.001,0.01); Compare TC, TG, LDL-C level (P＜0.001) in the reduction rat blood serum of three equal highly significants of dosage group of the red compound recipe system of sugarcane with the blank group; The red compound recipe system low dose of sugarcane has trend of rising to HDL-C, but there was no significant difference, middle dosage and the heavy dose HDL-C level (P＜0.01,0.001) (table 1) that all can significantly raise, and all above-mentioned effects and Monas cuspurpureus Went or lovastatin group are similar or strong slightly.
The red compound recipe system of table 1 sugarcane is to the influence of rat blood serum triglyceride, cholesterol, low density lipoprotein, LDL, HDL-C (n=10, mean ± SD)
Compare with the normal control group
△ △P＜0.01,
△ △ △P＜0.001; Compare with the blank group
*P＜0.05,
*P＜0.01,
* *P＜0.001
The present invention is described according to preferred embodiment.Should be understood that the description of front and embodiment are just to illustrating the present invention.Under prerequisite without departing from the spirit and scope of the present invention, those skilled in the art can design multiple alternative of the present invention and improvement project, and it all should be understood to be within protection scope of the present invention.
Claims (8)
1, a kind of composite lipid-regulation medicine is characterized in that with Monas cuspurpureus Went and Caulis Sacchari sinensis extract be principal agent.
2, medicine according to claim 1 wherein, calculates Monas cuspurpureus Went 1-60 part, Caulis Sacchari sinensis extract composition 1-5 part by weight.
3, medicine according to claim 2 wherein, calculates by weight, and Monas cuspurpureus Went is 2-60 part, Caulis Sacchari sinensis extract composition 2-3 part.
4,, wherein, if desired, can also comprise acceptable accessories according to the described medicine of claim 1-3.
5, according to the described medicine of claim 1-3, it is characterized by compound preparation, the per unit compound preparation contains Monas cuspurpureus Went 10～300mg, Caulis Sacchari sinensis extract 1～300mg.
6, according to the described medicine of claim 1-5, wherein said Caulis Sacchari sinensis extract contains compositions such as many arachyl alcohols, Polyphenols polyphenoils, plant sterol, oligomeric xylose; Preferred described Caulis Sacchari sinensis extract contains and is not less than many arachyl alcohols of 90%.
7, according to the described medicine of claim 1-7, wherein said Caulis Sacchari sinensis extract is to make by the method that comprises one of following or a plurality of steps:
(1) extracts many arachyl alcohols;
(2) extract the Polyphenols polyphenoils;
(3) extract plant sterol;
(4) extract oligomeric xylose.
8, the application of the described medicine of claim 1-8 is characterized in that preparing the medicine that is used for the treatment of hyperlipemia or atherosclerosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100043035A CN101491648A (en) | 2008-01-21 | 2008-01-21 | Composite lipid adjustment medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100043035A CN101491648A (en) | 2008-01-21 | 2008-01-21 | Composite lipid adjustment medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101491648A true CN101491648A (en) | 2009-07-29 |
Family
ID=40922548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100043035A Pending CN101491648A (en) | 2008-01-21 | 2008-01-21 | Composite lipid adjustment medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101491648A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102351642A (en) * | 2011-08-03 | 2012-02-15 | 中国林业科学研究院资源昆虫研究所 | Refining method of high-grade alkanol |
| CN103755524A (en) * | 2014-01-15 | 2014-04-30 | 王中华 | Preparation method of policosanol |
| CN105533747A (en) * | 2015-12-31 | 2016-05-04 | 哈药集团技术中心 | Health food capable of assisting in reduction of blood fat |
| CN109651089A (en) * | 2018-12-26 | 2019-04-19 | 杭州余杭博士达油脂有限公司 | A method of using rice bran hair wax as waste n-octacosanol |
| WO2021193920A1 (en) * | 2020-03-27 | 2021-09-30 | 東レ株式会社 | Powdered oligosaccharide composition |
-
2008
- 2008-01-21 CN CNA2008100043035A patent/CN101491648A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102351642A (en) * | 2011-08-03 | 2012-02-15 | 中国林业科学研究院资源昆虫研究所 | Refining method of high-grade alkanol |
| CN103755524A (en) * | 2014-01-15 | 2014-04-30 | 王中华 | Preparation method of policosanol |
| CN103755524B (en) * | 2014-01-15 | 2016-07-06 | 王中华 | A kind of preparation method of policosanol |
| CN105533747A (en) * | 2015-12-31 | 2016-05-04 | 哈药集团技术中心 | Health food capable of assisting in reduction of blood fat |
| CN109651089A (en) * | 2018-12-26 | 2019-04-19 | 杭州余杭博士达油脂有限公司 | A method of using rice bran hair wax as waste n-octacosanol |
| WO2021193920A1 (en) * | 2020-03-27 | 2021-09-30 | 東レ株式会社 | Powdered oligosaccharide composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI106265B (en) | Process for preparing xylitol from xylose-containing mixtures | |
| CN110845328B (en) | Method for preparing high-purity carnosic acid from rosemary ointment byproducts | |
| JP5013348B2 (en) | How to get sphingolipid | |
| CN101491648A (en) | Composite lipid adjustment medicine | |
| CN102675398B (en) | A kind of method extracting momordica grosvenori glycoside V and farnesol from Grosvenor Momordica | |
| US6376682B1 (en) | Compound with α-glucosidase inhibiting action and method for producing the same | |
| CN114177218B (en) | Mulberry leaf extract rich in 1-deoxynojirimycin and preparation method thereof | |
| CN111393400A (en) | Method for preparing squalene, vitamin E and sterol from fructus momordicae seed kernels | |
| KR20200000005A (en) | Method of increased recovery of specific ginsenoside | |
| CN1240407C (en) | Chinese-medicinal extract with alpha-glucosidase inhibitor activity, and its preparing process and application | |
| CN111117773A (en) | Method for separating nervonic acid from garlic oil and application thereof | |
| EP1559703B1 (en) | A natural compound useful for treating diabetes, its preparation and use | |
| JP4223579B2 (en) | Method for producing xylose and xylitol | |
| EP1747000B1 (en) | Ethanol extraction of phytosterols from corn fiber | |
| CN107286264A (en) | The deep working method of Chinese date nutrient material separation | |
| CN102477453A (en) | Method of preparing taxifolin monomer from engelhardtia leaf and application | |
| CN101491675A (en) | Composite lipid-regulation medicine | |
| CN105456277B (en) | Application of the ganodenic acid acid activity position in preparing blood fat reducing health products and drug | |
| CN102690359A (en) | Method for extracting starch and cucurbitacins from siraitia grosvenorii roots | |
| CN102719485B (en) | A kind of method of Starch Conversion ethanol in root tuber using Momordica grosvenori | |
| CN105384626A (en) | Method for separating and purifying p-coumaric acid in bamboo shavings | |
| JPWO2007069733A1 (en) | Method and apparatus for producing ceramide-related substances using alkaline aqueous solution | |
| CN110063504A (en) | A kind of natural dietary fiber replenishers and preparation method thereof with effect for reducing fat | |
| CN110090243A (en) | A kind of Semen euryales extract for Postprandial glucose control, preparation method and application | |
| CN111228253B (en) | Application of amomum kravanh extract in preparation of alpha-glucosidase inhibitor medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20090729 |